Propofol

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1989

www.ebi.ac.uk

First approval year: 1989
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Propofol
www.ebi.ac.uk

Molecular weight: 178.27
www.ebi.ac.uk

Structure (SMILES): CC(C)c1cccc(C(C)C)c1O
www.ebi.ac.uk

diprivan
Diprivan
disoprivan
Disoprivan
propofol
Propofol
propofol component of ketafol
Propofol component of ketafol
rapinovet
Rapinovet

Arm I (Propofol)
arm i propofol
Diprivan
disoprofol
Disoprofol
Drug-Induced Sleep Endoscopy (Propofol)
fresofol
Fresofol
ici 35 868
ICI 35-868
ICI 35,868
ici 35868
ICI-35868
ici35 868
ICI35,868
Injection Propofol
ketafol component propofol
KETAFOL COMPONENT PROPOFOL
lipuro
Lipuro
nsc 5105
NSC-5105
phenol 2 6 bis 1 methylethyl
Phenol, 2,6-bis(1-methylethyl)
propofol

And 59 more, listed on the interactive page.

ATC classification codes

N01AX10

Sources for recorded values

www.ebi.ac.uk

CAS registry numbers

2078-54-8

ChEMBL ID: CHEMBL526
www.ebi.ac.uk

InChIKey: OLBCVFGFOZPWHH-UHFFFAOYSA-N
www.ebi.ac.uk

PubChem compound IDs

4943

RxNorm IDs (RxCUI)

8782

FDA ingredient codes (UNII)

YI7VU623SF

Applicant: FRESENIUS KABI USA
Approval date: 2 Oct 1989
Application number: NDA019627

First in class: No
Orphan designation: No
Availability: Prescription only

Pharmacology name: propofol
Type: Synthetic organic
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Parenteral

Action
Inhibition
Action type
Inhibitor
Target
Piezo1
Gene symbol
PIEZO1
Protein identifier
Q92508
Action
Inhibition
Action type
Inhibitor
Target
Piezo2
Gene symbol
PIEZO2
Protein identifier
Q9H5I5
Action
Inhibition
Action type
Inhibitor
Target
TRPV4
Gene symbol
TRPV4
Protein identifier
Q9HBA0
Median affinity
4.41
Affinity units
pIC50
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
O00591
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
O14764
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P14867
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P18505
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P18507
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P28472
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P31644
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P34903
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P47869
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P47870
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P48169
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
P78334
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
Q16445
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
Q8N1C3
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
Q99928
Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE_ALLOSTERIC_MODULATOR
Target
GABA-A receptor; anion channel
Protein identifier
Q9UN88

Open Targets mechanisms

Mechanism
GABA-A receptor; anion channel positive allosteric modulator
Action type
POSITIVE ALLOSTERIC MODULATOR
Target
GABA-A receptor; anion channel

Action type
POSITIVE ALLOSTERIC MODULATOR
Gene symbol
GABRA1|GABRG2|GABRB3
Protein identifier
P14867|P18507|P28472
Organism
Homo sapiens
Target development level
Clinical
Action type
POSITIVE ALLOSTERIC MODULATOR
Gene symbol
GABRA1|GABRG2|GABRB2
Protein identifier
P14867|P18507|P47870
Organism
Homo sapiens
Target development level
Clinical
Action type
POSITIVE ALLOSTERIC MODULATOR
Gene symbol
GABRG2|GABRA2|GABRB2
Protein identifier
P18507|P47869|P47870
Organism
Homo sapiens
Target development level
Clinical

Condition
Atrial Fibrillation
Highest recorded phase
3
Condition identifier
EFO:0000275
Subject identifier
D001281
Condition
Hypertension
Highest recorded phase
3
Condition identifier
EFO:0000537
Subject identifier
D006973
Condition
Wounds and Injuries
Highest recorded phase
2
Condition identifier
EFO:0000546
Subject identifier
D014947
Condition
Leukemia
Highest recorded phase
2
Condition identifier
EFO:0000565
Subject identifier
D007938
Condition
Neoplasms
Highest recorded phase
3
Condition identifier
EFO:0000616
Subject identifier
D009369
Condition
Adenomatous Polyposis Coli
Highest recorded phase
3
Condition identifier
EFO:0000662
Subject identifier
D011125
Condition
Severe Acute Respiratory Syndrome
Highest recorded phase
3
Condition identifier
EFO:0000694
Subject identifier
D045169
Condition
Stroke
Highest recorded phase
3
Condition identifier
EFO:0000712
Subject identifier
D020521
Condition
Subarachnoid Hemorrhage
Highest recorded phase
3
Condition identifier
EFO:0000713
Subject identifier
D013345
Condition
Obesity
Highest recorded phase
3
Condition identifier
EFO:0001073
Subject identifier
D009765
Condition
Obesity, Morbid
Highest recorded phase
2
Condition identifier
EFO:0001074
Subject identifier
D009767
Condition
Liver Cirrhosis
Highest recorded phase
3
Condition identifier
EFO:0001422
Subject identifier
D008103
Condition
Coronary Disease
Highest recorded phase
2
Condition identifier
EFO:0001645
Subject identifier
D003327
Condition
Pancreatic Neoplasms
Highest recorded phase
3
Condition identifier
EFO:0002618
Subject identifier
D010190
Condition
Reperfusion Injury
Highest recorded phase
3
Condition identifier
EFO:0002687
Subject identifier
D015427
Condition
Heart Diseases
Highest recorded phase
3
Condition identifier
EFO:0003777
Subject identifier
D006331
Condition
Pain
Highest recorded phase
3
Condition identifier
EFO:0003843
Subject identifier
D010146
Condition
Intestinal Polyps
Highest recorded phase
2
Condition identifier
EFO:0003855
Subject identifier
D007417
Condition
Breast Neoplasms
Highest recorded phase
3
Condition identifier
EFO:0003869
Subject identifier
D001943
Condition
Intracranial Aneurysm
Highest recorded phase
3
Condition identifier
EFO:0003870
Subject identifier
D002532
Condition
Renal Insufficiency, Chronic
Highest recorded phase
1
Condition identifier
EFO:0003884
Subject identifier
D051436
Condition
Premature Birth
Highest recorded phase
1
Condition identifier
EFO:0003917
Subject identifier
D047928
Condition
Sleep Apnea, Obstructive
Highest recorded phase
2
Condition identifier
EFO:0003918
Subject identifier
D020181
Condition
Osteonecrosis
Highest recorded phase
0.5
Condition identifier
EFO:0004259
Subject identifier
D010020
Condition
Scoliosis
Highest recorded phase
1
Condition identifier
EFO:0004273
Subject identifier
D012600

And 33 more, listed on the interactive page.

Condition identifier
EFO_0000217
Condition identifier
EFO_0000246
Condition identifier
EFO_0000266
Condition identifier
EFO_0000275
Highest recorded phase
3
Condition identifier
EFO_0000537
Highest recorded phase
3
Condition identifier
EFO_0000565
Condition identifier
EFO_0000616
Highest recorded phase
3
Condition identifier
EFO_0000662
Highest recorded phase
3
Condition identifier
EFO_0000712
Highest recorded phase
3
Condition identifier
EFO_0000713
Highest recorded phase
3
Condition identifier
EFO_0001072
Highest recorded phase
1
Condition identifier
EFO_0001073
Highest recorded phase
3
Condition identifier
EFO_0001074
Condition identifier
EFO_0001422
Highest recorded phase
3
Condition identifier
EFO_0001645
Highest recorded phase
3
Condition identifier
EFO_0002687
Highest recorded phase
3
Condition identifier
EFO_0002950
Highest recorded phase
2
Condition identifier
EFO_0003776
Highest recorded phase
1
Condition identifier
EFO_0003777
Highest recorded phase
3
Condition identifier
EFO_0003818
Condition identifier
EFO_0003855
Highest recorded phase
2
Condition identifier
EFO_0003869
Highest recorded phase
3
Condition identifier
EFO_0003870
Highest recorded phase
3
Condition identifier
EFO_0003884
Highest recorded phase
1
Condition identifier
EFO_0003917
Highest recorded phase
1

And 179 more, listed on the interactive page.

Event
agitation
Reports
178
Reporting signal score
112.828
Event
airway complication of anaesthesia
Reports
35
Reporting signal score
145.797
Event
anaesthetic complication
Reports
66
Reporting signal score
166.789
Event
anaphylactic reaction
Reports
486
Reporting signal score
754.843
Event
anaphylactic shock
Reports
847
Reporting signal score
2,518.49
Event
anaphylactoid shock
Reports
33
Reporting signal score
106.008
Event
arthralgia
Reports
12
Reporting signal score
139.302
Event
blood pressure decreased
Reports
164
Reporting signal score
132.279
Event
bradycardia
Reports
337
Reporting signal score
358.721
Event
bronchospasm
Reports
324
Reporting signal score
766.447
Event
cardiac arrest
Reports
335
Reporting signal score
612.988
Event
cardio-respiratory arrest
Reports
98
Reporting signal score
170.393
Event
circulatory collapse
Reports
192
Reporting signal score
387.436
Event
delayed recovery from anaesthesia
Reports
114
Reporting signal score
460.565
Event
diabetes insipidus
Reports
46
Reporting signal score
104.465
Event
diarrhoea
Reports
30
Reporting signal score
223.819
Event
dizziness
Reports
52
Reporting signal score
108.664
Event
dystonia
Reports
89
Reporting signal score
110.033
Event
electrocardiogram st segment elevation
Reports
59
Reporting signal score
116.763
Event
fall
Reports
11
Reporting signal score
131.428
Event
fatigue
Reports
45
Reporting signal score
210.791
Event
generalised erythema
Reports
79
Reporting signal score
144.184
Event
haemodynamic instability
Reports
99
Reporting signal score
213.911
Event
headache
Reports
65
Reporting signal score
124.956
Event
hyperthermia malignant
Reports
162
Reporting signal score
650.429

And 29 more, listed on the interactive page.

NCT00142493
clinicaltrials.gov
NCT00187135
clinicaltrials.gov
NCT00436345
clinicaltrials.gov
NCT01342835
clinicaltrials.gov
NCT01387139
clinicaltrials.gov
NCT02203175
clinicaltrials.gov
NCT03841812
clinicaltrials.gov
NCT04062123
clinicaltrials.gov
NCT04947345
clinicaltrials.gov
NCT05486819
clinicaltrials.gov
NCT06034873
clinicaltrials.gov
NCT00209521
clinicaltrials.gov
NCT01948765
clinicaltrials.gov
NCT00265616
clinicaltrials.gov
NCT00336882
clinicaltrials.gov
NCT00538616
clinicaltrials.gov
NCT01007773
clinicaltrials.gov
NCT04034771
clinicaltrials.gov
NCT00337051
clinicaltrials.gov
NCT00389883
clinicaltrials.gov
NCT00418457
clinicaltrials.gov
NCT00478907
clinicaltrials.gov
NCT00671931
clinicaltrials.gov
NCT00695214
clinicaltrials.gov
NCT05303987
clinicaltrials.gov

And 56 more, listed on the interactive page.

Route: Intravenous

Discard unused after 28 days
Use aseptic technique
Use within 28 days after opening

Hydrogen bond acceptors: 1
Hydrogen bond donors: 1
Polar surface area: 20.23
Calculated partition coefficient (ALogP): 3.64
Calculated partition coefficient (XLogP): 3.8
Prodrug: No
Chirality: Achiral
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 2
Heavy atoms: 13
Molecular formula: C12H18O
Monoisotopic mass: 178.135765193
Natural product: Yes

0069-0209
0069-0234
0069-0248
0409-0010
0409-0501
0409-1511
0409-4699
0409-6010
0641-6194
0641-6195
0641-6196
16714-528
16714-690
16714-977
23155-345
25021-608
43598-265
43598-548
43598-549
63323-269
65219-800
71288-729
71288-730
71288-731
72572-590

And 10 more, listed on the interactive page.

Recorded assays: 3,799
Active assays: 172

Confirmatory
Other
Screening
Summary

Hypnotics and Sedatives
id.nlm.nih.gov
Anesthetics, Intravenous
id.nlm.nih.gov

These details could not be displayed.

Related records

Trials (1,327)

"Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail
A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation
A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery Patients
A Comparative Study Between Combination of Propofol and Dexmedetomidine Versus Propofol Alone in Anesthesia for Rigid Bronchoscopy by Using the Patient State Index Monitor
A Comparative Study of Depth of Anesthesia Monitored by Bispectral Index (BIS) Values
A Comparative Study of Eleveld and Schnider Pharmacokinetic Models for Target-Controlled Infusion of Propofol in Sedation of Mechanically Ventilated ICU Patients
A Comparison Between Propofol and Etomidate in Hysteroscopy on Effect of Postoperative Sedation and Cognitive Function in Elderly Patients
A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit
A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation
A Comparison of Efficacy and Safety During Endoscopic Submucosal Dissection Between Dexmedetomidine-remifentanil and Propofol-remifentanil
A Comparison of Injection Pain of Propofol During Endoscopy : LCT Propofol vs MCT/LCT Propofol
A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters
A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver Transplantation
A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Renal Protection During Deceased Brain Dead Donor Kidney Transplantation - A Prospective, Randomized Trial
A Comparison of Remimazolam Besylate and Propofol Sedation in Patients Undergoing Colonoscopic Polypectomy
A Comparison of Surgical Outcome Following Drug-induced Sleep Endoscopic Diagnosis Using Propofol or Dexmedetomidine for Sedation : A Prospective Randomized Trial
A Comparison of the Sedation During Endoscopy in Children
A Comparison of Totally Intravenous and Inhalation Anesthesia for Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy

In development for (47)

Acute respiratory distress syndrome Phase 3
Atrial fibrillation Phase 3
Brain aneurysm Phase 3
Brain injury Phase 3
Breast neoplasm Phase 3
Cancer Phase 3
Cerebral arterial disease Phase 3
Chronic kidney disease Phase 1
Cirrhosis of liver Phase 3
Colon adenocarcinoma Phase 2
Colorectal cancer Phase 1
Coronary artery disorder Phase 2
Delirium Phase 3
Depressive disorder Early phase 1
Dissociative amnesia Phase 1
Esophageal cancer Phase 3
Exocrine pancreatic carcinoma Phase 3
Heart disorder Phase 3
Hypertensive disorder Phase 3
Hypotensive disorder Phase 2

Targets (16)

GABRA1 GABA-A receptor; anion channel positive allosteric modulator
GABRA2 GABA-A receptor; anion channel positive allosteric modulator
GABRA3 GABA-A receptor; anion channel positive allosteric modulator
GABRA4 GABA-A receptor; anion channel positive allosteric modulator
GABRA5 GABA-A receptor; anion channel positive allosteric modulator
GABRA6 GABA-A receptor; anion channel positive allosteric modulator
GABRB1 GABA-A receptor; anion channel positive allosteric modulator
GABRB2 GABA-A receptor; anion channel positive allosteric modulator
GABRB3 GABA-A receptor; anion channel positive allosteric modulator
GABRD GABA-A receptor; anion channel positive allosteric modulator
GABRE GABA-A receptor; anion channel positive allosteric modulator
GABRG1 GABA-A receptor; anion channel positive allosteric modulator
GABRG2 GABA-A receptor; anion channel positive allosteric modulator
GABRG3 GABA-A receptor; anion channel positive allosteric modulator
GABRP GABA-A receptor; anion channel positive allosteric modulator
GABRQ GABA-A receptor; anion channel positive allosteric modulator

Propofol

Development status

Names and chemistry

Brand names (10)

Other names (84)

Identifiers

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (19)

Open Targets mechanisms

DrugCentral mechanisms (3)

Investigated indications (58)

Open Targets indications (204)

Reported adverse events (54)

Trial references (81)

Dosing

Conditions of use (3)

Chemical properties

National Drug Codes

Evidence counts

Active assay types (4)

Pharmacologic actions

Biological measurements

Related records

Trials (1,327)

In development for (47)

Other linked conditions (9)

Targets (16)